| Literature DB >> 26526897 |
Shashi G Amur1, Sarmistha Sanyal1, Aloka G Chakravarty2, Marianne H Noone1, James Kaiser1, Susan McCune1, ShaAvhree Y Buckman-Garner1.
Abstract
The traditional route for regulatory acceptance of biomarkers in drug development is through submission of biomarker data in drug approval submissions in the context of a single drug development program. The US FDA's Critical Path Initiative called for establishment of a biomarker qualification process to enable progress in the drug development paradigm. In response to this, the Center for Drug Evaluation and Research (CDER) established a Biomarker Qualification Program (BQP) to qualify a biomarker for a specific context of use (COU). The qualified biomarker can then be used in multiple drug development programs for this COU without re-review. Here, we describe some of the features of the BQP and two new initiatives that have the potential to aid biomarker development through early interactions with the FDA. Finally, we discuss some of the feedback the FDA has received from submitters and the BQP's actions to strengthen the program.Keywords: biomarker; context of use; critical path innovation meeting; evidentiary considerations; international harmonization; letter of support; qualification; regulatory science; statistical considerations; submitter
Mesh：
Substances：
Year: 2015 PMID： 26526897 DOI： 10.2217/bmm.15.90
Source DB: PubMed Journal: Biomark Med ISSN： 1752-0363 Impact factor: 2.851